BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Oculus Innovative Sciences, Inc. (OCLS) to Raise $3.1 Million in Registered Direct Offering


4/23/2012 9:31:01 AM

PETALUMA, Calif., April 23, 2012 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) announced today that it has entered into a definitive agreement with a single life science-focused institutional investor for the purchase of a combination of 1) 1,000 shares of its new Series A Convertible Preferred Stock at $1,000 per share, which are convertible into 1.1 million shares of its common stock and 2) 2.4 million of its common shares at $0.90 per share and 3) a 2.5-year warrant to purchase up to approximately 3.5 million of common stock at an exercise price of $1.18 per share, which is not exercisable for six months. The Series A Convertible Preferred has no dividend and is perpetual. Oculus Innovative Sciences, Inc will receive approximately $3.1 million in gross proceeds from the offering. The offering is expected to close on or about April 24, 2012, subject to customary closing conditions. Net proceeds from the offering will be used to fund the Company's clinical and regulatory programs for "Scar Reduction" indication and initiation of additional regulatory filings to expand Company's antimicrobial indication with the FDA in the surgical market as well as working capital needs and for general corporate purposes.

Read at GlobeNewswire

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES